Sanofi, Regeneron Allowed to Sell Cholesterol Drug

Feb 09, 2017

A federal appeals court said Regeneron Pharmaceuticals Inc. and Sanofi SA can continue selling their cholesterol drug, Praluent, while they appeal the order, according to a Reuters article.

A judge previously blocked sales of the drug after Amgen won a trial wherein it accused them of patent infringement. The order would have taken effect on Feb. 21.

Regeneron general counsel Joseph LaRosa said in a statement the company would continue to defend its case through the appeal process.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments